LAYERED (634A TSE Standard) September 29, 2026

Streamlining healthcare facility patient interactions and related operations

This report is an English translation of part of the report issued on September 29, 2026.
For inquiries concerning the report, please contract info@stock-r.org

【634A LAYERED Sector：Information & Communication】

Fiscal Year		Net sales (mn yen)	YoY (%)	Operating profit (mn yen)	YoY (%)	Ordinary profit (mn yen)	YoY (%)	Profit (mn yen)	YoY (%)	EPS (yen)	BPS (yen)	DPS (yen)
Jun. 2025		1,461	25.7	127	-	128	-	100	-	44.5	174.2	0.0
Jun. 2026		1,980	35.5	344	2.7x	337	2.6x	239	2.4x	106.5	280.7	0.0
Jun. 2027	f	2,474	24.9	458	33.1	432	28.2	305	27.6	119.8	-	0.0

Note: Non-consolidated basis.Figures for the fiscal year ending June 2027 is the company's forecasts.
It conducted 1:20 stock split on April 30, 2026. Per share indicies are adjusted retroactively.

Offering a Wide Range of Products for Medical Facilities Covering the Entire Patient Flow

LAYERED offers a suite of SaaS products designed to automate and streamline patient flow. Product functions include searching for medical facilities, making appointments, completing medical questionnaires, arriving and checking in to facilities, waiting for appointments, receiving consultation and medical instructions, completing payments and follow-ups after visits. A key characteristic of LAYERED is its multi-product strategy. This entails combining the necessary products to construct optimal workflows tailored to specific medical specialties and patient demographics.

Specifically, the most widely used product is the online medical questionnaire Symview, followed by the digital signage service Medicastar for medical institutions, patient management system Kakarite and appointment reservation system Wakumy, among others.

Approximately 6,000 medical institutions have adopted the company’s products. Its primary customers comprise clinics that conduct health insurance treatments. As of the end of fiscal year ended June 2026, the number of accounts, which is the total number of products in use at medical institutions, reached 8,451.

Instead of relying on large-scale systems, medical institutions can select and use only necessary products. In addition to being easy to implement, the extensive product lineup also ensures scalability. Even if a customer cancels one product, the relationship can be maintained, provided they continue using other products. This is one of the advantages of the company’s business.

Sales are primarily conducted through sales agents, including major pharmaceutical wholesalers and consultants that specialize in clinic opening support. However, the company also engages in inbound sales. In fiscal year ended June 2026, the proportion of medical institutions that signed contracts through agents reached approximately 70 percent. In particular, contracts secured through MEDIPAL HOLDINGS group accounted for about 40 percent of all contracts signed during that period.

Medical DX Stock, which comprises monthly subscription revenue from SaaS products, accounted for 55.2% of net sales for fiscal year ended June 2026. Medical DX Initial, which represents the upfront fees incurred when a customer first adopts the company’s services, accounted for 31.6% and advertising revenue accounted for 13.1%.

The contents indicated in the report are based on information as of the date the report was created and are subject to change without prior notice. The Stock Research Center makes no warranty or representation concerning the accuracy, reliability, completeness, adequacy and reliability of the information indicated in the report, and shall not assume no responsibility or obligation whatsoever. The Stock Research Center assumes no responsibility for any direct or indirect loss, lost profit, damage or other results from investors accessing and using the report or relying on the report concerning the distribution of the report. Final investment decisions shall be made by the investors themselves, and entire responsibility for investments lies with investors that accessed the report. In addition, intellectual rights concerning the report belongs to The Stock Research Center and may not be copied, reprinted, quoted, etc. without permission.

LAYERED (634A TSE Standard) **September 29, 2026**

Financial Statements

Statement of income / Fiscal Year	Jun. 2024		Jun. 2025		Jun. 2026	
	(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Net sales	1,162	100.0	1,461	100.0	1,980	100.0
Cost of sales	487	41.9	546	37.4	682	34.4
Gross profit	674	58.0	914	62.6	1,298	65.6
Selling, general and administrative expenses	692	59.6	787	53.9	954	48.2
Operating profit	-17	-1.5	127	8.7	344	17.4
Non-operating income	3	-	2	-	3	-
Non-operating expenses	0	-	1	-	11	-
Ordinary profit	-15	-	128	8.8	337	17.0
Profit before income taxes	-15	-	132	9.0	337	17.0
Net profit	-2	-	100	6.8	239	12.1

Balance sheet / Fiscal Year	Jun. 2024		Jun. 2025		Jun. 2026	
	(mn yen)	(%)	(mn yen)	(%)	(mn yen)	(%)
Current assets	463	79.3	654	84.3	976	88.0
Cash and deposits	283	48.5	421	54.3	642	57.9
Accounts receivable - trade	161	27.6	199	25.6	284	25.6
Inventories	8	1.4	17	2.2	31	2.8
Non-current assets	121	20.7	121	15.6	132	11.9
Property, plant and equipment	30	5.1	26	3.4	25	2.3
Intangible assets	56	9.6	62	8.0	62	5.6
Investments and other assets	34	5.8	33	4.3	44	4.0
Total assets	584	100.0	776	100.0	1,109	100.0
Current liabilities	197	33.7	261	33.6	379	34.2
Accounts payable	20	3.4	22	2.8	36	3.2
Current portion of long-term borrowings	13	2.2	23	3.0	23	2.1
Non-current liabilities	94	16.1	121	15.6	97	8.7
Long-term borrowings	80	13.7	108	13.9	84	7.6
Net assets	292	50.0	392	50.5	632	57.0
Owners' equity	291	49.8	391	50.4	631	56.9

Statement of cash flows / Fiscal Year	Jun. 2024	Jun. 2025	Jun. 2026
	(mn yen)	(mn yen)	(mn yen)
Cash flows from operating activities	-20	113	277
Depreciation	17	22	28
Cash flows from investing activities	-58	-12	-31
Cash flows from financing activities	-23	37	-24
Dividends paid	-	-	-
Net increase in cash and cash equivalents	-102	138	221
Cash and cash equivalents	283	421	642


Note:Non-consolidated
Source: Prepared by Stock Research Center based on the notifiable prospectus.

The contents indicated in the report are based on information as of the date the report was created and are subject to change without prior notice. The Stock Research Center makes no warranty or representation concerning the accuracy, reliability, completeness, adequacy and reliability of the information indicated in the report, and shall not assume no responsibility or obligation whatsoever. The Stock Research Center assumes no responsibility for any direct or indirect loss, lost profit, damage or other results from investors accessing and using the report or relying on the report concerning the distribution of the report. Final investment decisions shall be made by the investors themselves, and entire responsibility for investments lies with investors that accessed the report. In addition, intellectual rights concerning the report belongs to The Stock Research Center and may not be copied, reprinted, quoted, etc. without permission.

About Stock Research Center

Stock Research Center is engaged in the preparation of analyst reports, mainly on companies that are not sufficiently covered by analysts, based on a neutral perspective, and broadly disclose the reports to the public with an aim to revitalize the stock market.

Note: Reports prepared by Stock Research Center are created in reference to the Ministry of Economy, Trade and Industry's Guidance for Integrated Corporate Disclosure and Company-Investor Dialogues for Collaborative Value Creation.



■Supporting Members

Tokyo Stock Exchange, Inc.
Nomura Securities Co., Ltd.
KPMG AZSA LLC
Deloitte Touche Tohmatsu LLC
PricewaterhouseCoopers Japan LLC
GYOSEI & CO.
PRONEXUS INC.
The Securities Analysts Association of Japan
SMBC Nikko Securities Inc.
Mizuho Securities Co., Ltd.
ICMG Co., Ltd.
SBI SECURITIES Co., Ltd.
Ichiyoshi Securities Co., Ltd.
Avantia G.P.
Japan Securities Dealers Association
Daiwa Securities Co. Ltd.
Ernst & Young ShinNihon LLC
Grant Thornton Taiyo LLC
BDO Sanyu
A&A Partners
TAKARA PRINTING CO., LTD.

■Endorsement

Nagoya Stock Exchange, Inc.
Japan Venture Capital Association
Institutional Investors Collective Engagement Forum
Sapporo Securities Exchange
Japan Investor Relations Association
Fukuoka Stock Exchange
Japan Stewardship Forum

Certification by Analysts

Analysts indicated in the reports certify that the content indicated in the report precisely reflects the personal opinions of the analysts on all securities and issuer companies discussed in the report. In addition, it is ensured that the opinions directly or indirectly indicated in the report will have no influence on the analyst's compensation in the past, present, and future upon writing the report.

Disclaimer

- The report is prepared by stock analysts affiliated with the Stock Research Center for the purpose of disclosure to a wide range of investors as reference information and not to recommend or solicit to buy or to sell any particular securities or financial instrument.
- The content and indication of the report is based on disclosed information available publicly and is prepared by adding necessary supplementary information gained through interviews by analysts. The writer of the report is, without exception, prohibited to use insider information, or to acquire such information. The information included in the report is believed to be precise and reliable, but its preciseness is not verified objectively. In addition, the report is not intended to comprehensively include all information required by investors.
- The information included in the report may become outdated due to changes in the financial market, economic environment, etc. There are risks that the prices of stocks featured directly or indirectly in the report will fall below the par value due to fluctuations in stock prices, changes in management/financial conditions of the issuers, fluctuations in exchange rates or interest rates, etc. Past performance does not imply or guarantee future performance.
- The opinions indicated in the report are subject to change without notice and the Stock Research Center has no obligation to update the information or opinions included in the report.
- The Stock Research Center does not bear any responsibility for any results, including direct losses, indirect losses, losses of profit and damages, suffered by investors due to using the report or relying on the report. Final investment decisions shall be made by investors themselves and the sole responsibility concerning the investment lies with the investors that viewed the report.
- The copyright of the report belongs to the Stock Research Center and it may not be copied, reproduced, quoted, etc. in any form without prior consent.